Share on LinkedInShare on LinkedIn

ARTICLE · 22 APRIL 2013

Evergreening

A discussion on the decision of the Indian Supreme Court to deny Novartis’s application for patent protection for an improved version of its patented Glivec drug.

South AfricaIntellectual Property

The decision of the Indian Supreme Court to deny Novartis’s application for patent protection for an improved version of its patented Glivec drug – the culmination of a seven-year battle - has certainly made the headlines. There are a number of reasons for this. First, Glivec is a well-known drug – described by some as a ‘wonder drug’ – that’s used to combat cancer, including  leukaemia and gastro-intestinal cancer. Second,  pharmaceutical patents are inherently controversial because they’re emotive – pharmaceutical companies argue that they deserve as much protection as they can get because so much research and development goes into drugs,  whereas civil society often argues that patents allow the drugs companies to charge a premium, thereby placing life-saving drugs beyond the reach of much of the world’s population . And third, the Glivec case dealt with the issue  of ‘evergreening’,  which is the practice of patenting modifications  or improvements to a patented

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from